A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice

Sponsor
Novo Nordisk A/S
Study ID
NCT07055607
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    Participants will be treated with commercially available Wegovy according to routine clinical practice and is purely at the discretion of the treating physician. Only individuals receiving Wegovy reimbursed by the healthcare system in their respective countries are included in the study.

Study Details

This observational study will explore how Wegovy® (Semaglutide) is used in everyday situations, how it might affect things like weight, body mass index (BMI) and waist circumference, and what kind of impact it could have on overall quality of life. The overall purpose of this study is to understand how Wegovy impacts weight when used as part of regular medical care. Participants will be treated with Wegovy as prescribed to the participant by their doctor, in accordance with normal clinical practice. The study will last for about two years.

Key Dates

Start date
May 1, 2025
Status verified
May 2026
Primary completion
Aug 15, 2028
Completion
Aug 15, 2028

Study Design

Enrollment
1,250 participants (estimated)

Arms

  • Arm: Wegovy®
    Participants will be treated with Wegovy according to the local labels in Spain, Switzerland and the United Kingdom (UK).

Primary Outcome Measure

Absolute change in body weight (kilograms [kg]) [ Time Frame: From baseline (0 months) to the end of observation (24 months) ]

Related Studies